HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Continues Legal Sparring With Cosmetic Eyelash-Growth Brands

This article was originally published in The Rose Sheet

Executive Summary

Latisse marketer Allergan continues to lock horns with cosmetic firms offering non-FDA-approved, prostaglandin-based eyelash-enhancement products, pursuing injunction and damages in California court.

You may also be interested in...



Tennessee AG Settles With Cosmetic Lash-Enhancer Brands; Sales Cease

Two cosmetics companies have settled charges filed by Tennessee’s Office of the Attorney General concerning eyelash-enhancement products that require FDA approval, according to the AG’s release. Tennesseans will no longer have access to Nutra Luxe’s Beautylash products or Peter Thomas Roth’s Lashes to Die For as a result of the agreement.

In Brief

Latisse maker Allergan prevails in California district court over cosmetic eyelash-enhancement marketer Athena Cosmetics, which has been enjoined from selling RevitaLash in the U.S. More news in brief.

Coty/Rimmel Targeted With Suit Over Lash Accelerator Claims

Lawsuit seeking class-action status against Coty alleges that lengthening and multiplying claims for the firm’s Rimmel London Lash Accelerator are “false, misleading and are reasonably likely to deceive the public.”

Related Content

UsernamePublicRestriction

Register

RS017616

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel